概要
BrainChild Bio is a clinical stage biotech developing CAR T cell therapies for tumors of the central nervous system. Its lead candidate BCB-276 is a B7-H3-targeted autologous CAR T therapy for diffuse intrinsic pontine glioma, delivered directly into cerebrospinal fluid through an in-dwelling reservoir catheter.
資金調達
| ラウンド |
金額 |
発表日 |
投資家 |
|
Series A
|
会員限定 |
会員限定 |
投資家 2社 |